- Research article
- Open Access
Gene expression profiles associated with cigarette smoking and moist snuff consumption
Received: 20 September 2016
Accepted: 7 February 2017
Published: 14 February 2017
Abstract
Background
Among the different tobacco products that are available on the US market, cigarette smoking is shown to be the most harmful and the effects of cigarette smoking have been well studied. US epidemiological studies indicate that non-combustible tobacco products are less harmful than smoking and yet very limited biological and mechanistic information is available on the effects of these alternative tobacco products. For the first time, we characterized gene expression profiling in PBMCs from moist snuff consumers (MSC), compared with that from consumers of cigarettes (SMK) and non-tobacco consumers (NTC).
Results
Microarray analysis identified 100 differentially expressed genes (DEGs) between the SMK and NTC groups and 46 DEGs between SMK and MSC groups. However, we found no significant differences in gene expression between MSC and NTC. Both hierarchical clustering and principle component analysis revealed that MSC and NTC expression profiles were more similar than to SMK. Random forest classification identified a subset of DEGs which predicted SMK from either NTC or MSC with high accuracy (AUC 0.98).
Conclusions
PMBC gene expression profiles of NTC and MSC are similar to each other, while SMK exhibit distinct profiles with alterations in immune related pathways. In addition to discovering several biomarkers, these studies support further understanding of the biological effects of different tobacco products.
Trial registration
ClinicalTrials.gov. Identifier: NCT01923402. Date of Registration: August 14, 2013. Study was retrospectively registered.
Keywords
- Gene expression
- Biomarkers
- Smoking
- Moist snuff
- qRT-PCR
- PBMC
Background
The long-term health consequences of cigarette smoking have been well documented [1]. For example, cigarette smoking is a major risk factor for lung cancer, Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases (CVD), and smokers experience higher rates of mortality relative to non-smokers for these disease states [1, 2]. Cigarette smoking is known to exert local (lung and buccal cavity) and systemic effects, and hence adversely impacts multiple organ systems. Smoking-induced oxidative stress and inflammation are hypothesized as key mechanisms that drive smoking induced diseases [2]. Smoking has been known to alter key signaling pathways and suppress immune responses, among other physiological processes [2]. At cellular and molecular levels, chronic smoking induces a wide range of macromolecular and biochemical changes. For example, several investigators have identified differentially expressed genes in several organ/tissue systems, including lung [3], nasal epithelia [4], buccal cells [4] and peripheral blood mononcuclear cells (PBMCs) [5–7] in smokers. Genes affected by cigarette smoke include those involved in cell survival, inflammation, tumor suppression, and apoptosis and are implicated in smoking-related diseases [8].
Smokeless Tobacco Products (STPs) are a diverse category of tobacco products that are consumed worldwide. Consumption of STPs may be associated with an increased risk for oral and other cancers as well as increased risk of mortality from ischemic heart diseases, depending on the type of product usage [9]. Fermented moist snuff, or dipping tobacco, is the widely consumed oral STP in the US [10]. Existing US epidemiological data suggests moist snuff consumption is generally associated with reduced health risks, relative to smoking, although risk for certain CVD mortality is elevated compared to non-consumers of tobacco [9, 11].
Findings from epidemiological studies among cigarette smokers and smokeless tobacco users in the US indicate that relative to never tobacco use, smokeless tobacco use has been associated with less mortality than cigarette smoking. In particular, data from the American Cancer Society’s Cancer Prevention Study II (CPS-II) indicate, among male smokeless tobacco users compared with male never users of tobacco, the adjusted risks of mortality (i.e., hazard ratios) were 1.28 (95% CI: 0.71-2.32) for chronic obstructive pulmonary disease; 2.00 (95% CI: 1.23-3.24) for lung cancer; 1.26 (95% CI: 1.08-1.47) for coronary heart disease; and 0.90 (95% CI: 0.12-6.71) for oropharynx cancer [12]. In contrast, data from the CPS-II indicate, among male cigarette smokers compared with male never users of tobacco, the adjusted risks of mortality (i.e., hazard ratios) were 10.8 (95% CI: 8.4-13.9) for chronic obstructive pulmonary disease; 21.3 (95% CI: 17.7-25.6) for lung cancer; and 1.9 (95% CI: 1.8-2.1) for coronary heart disease [13]. The relative risk of mortality from oropharynx cancer in this cohort of male cigarette smokers was estimated to be 27.48 (95% CI: 9.96-75.83) [14].
Given the overall burden of disease and mortality due to the consumption of tobacco products, particularly cigarette smoking, harm reduction efforts have led to the recognition of a continuum of risk among different tobacco product categories. Whereas combustible tobacco products such as cigarettes are identified as the most harmful, non-combustible tobacco products are associated with substantially lower harm, relative to the non-consumption of any tobacco as the baseline risk in US [15–17]. Additionally, the available epidemiological data from Sweden among snus (Swedish-type of oral, non-combustible tobacco) supports the reduced risk and harm of non-combustible tobacco relative to cigarettes [18, 19]. Briefly, snus is manufactured from ground air- or sun-cured tobacco and other ingredients using a heat-treatment process that differs from the process of manufacturing of US-style moist snuff [18].
While the harmful effects of cigarette smoking have been extensively investigated and are better understood, the effects of STPs, including moist snuff remain incompletely understood. Previous work from RAI companies evaluated the long-term effects of consumption of moist snuff and cigarette smoking and evaluated several biomarkers of exposure (BioExp) and biomarkers of effect (BioEff) in cross-sectional studies. In the first study, in addition to several BioExp, some biomarkers related to CVD were evaluated [20–22]. A second study, termed biomarker discovery study, focused on BioExp and BioEff in a different study cohort [23, 24]. Although the moist snuff consumer cohort (MSC) in both studies exhibited higher levels of nicotine biomarkers and tobacco specific nitrosamine biomarkers (TSNAs) compared to the smoker cohort (SMK), combustion-related biomarkers in the MSC were comparable to that found in the non-tobacco consumer cohort (NTC) in both studies referenced above. Select BioEff, including those associated with arachidonic acid metabolism, were elevated in both studies in SMK relative to MSC and NTC [22, 23]. Further, global metabolomic evaluation of plasma, saliva and urine collected in the biomarker discovery revealed that SMK exhibit distinct metabolite profiles compared to MSC and NTC cohorts [24]. Overall, BioEff indicative of vitamins C and E, and purine metabolism were altered in SMK, possibly due to increased oxidative stress and inflammatory responses in that cohort, relative to the MSC and NTC [24].
In our continuing efforts to further characterize the physiological changes in long-term smokers and moist snuff consumers, and to identify potential BioEff we have investigated global gene expression changes in the tobacco consumers in the biomarker discovery study cohorts (i.e., SMK, MSC and NTC). Additionally, these studies offer an opportunity to evaluate the concept of risk continuum among tobacco products at a molecular level. PBMCs collected from the study subjects in the biomarker study were utilized in this global gene expression profiling study.
Methods
Study design and population
The study design and the cohort characteristics have been previously described [23]. Briefly, this was a single-blind, cross-sectional study of healthy volunteers conducted at the High Point Clinical Trials Center, High Point, NC, USA. The inclusion criteria for cigarette smoker (SMK) group were: males aged 35–60 years; exclusive cigarette smoker of any brand with ≥6 mg “tar”/cigarette by Cambridge Filter Method1; consumption of ≥10 cigarettes/day for ≥3 years according to self-report; and expired carbon monoxide (ECO) level 10–100 ppm. The inclusion criteria for moist snuff consumer (MSC) group were: exclusive moist snuff consumer of any brand; consumption of ≥2 cans moist snuff per week for ≥3 years according to self-report; and ECO level 0–5 ppm. The inclusion criteria for non-smoker (NTC) group were: individuals reporting non-use of any tobacco or nicotine-containing products for ≥5 years with an ECO level of 0–5 ppm. Subjects provided written informed consent upon enrollment. The study conformed to ICH Good Clinical Practice guidelines and was conducted according to the principles of the Declaration of Helsinki. The study was approved by a central institutional review board (Independent Investigational Review Board, Inc., Plantation, FL, USA), and registered at ClinicalTrials.gov (ClinicalTrials.gov number: NCT01923402). Additional details on the subject demographics are summarized in Additional file 1: Supplementary Methods.
Blood sampling, PBMC preparation, and cell type analysis
Blood samples were collected from each subject on the morning of day 1, under fasting conditions and before tobacco consumption. Blood was processed within 2 h of blood collection. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood as described previously [23, 25]. Blood samples were mixed with Isolymph (CTL Scientific Supply Corp., Deer Park, NY, USA) and incubated for 45 min, and the leukocyte layer was removed and centrifuged at 200 x g for 10 min at room temperature. After removal of the supernatant, the cell pellet was resuspended in PBS at a ratio of PBS:volume of top layer leukocytes drawn of 2:5 mL. Five ml of cell suspension was layered onto 3 mL of Isolymph in 15 mL conical tubes and centrifuged at 400 x g for 45 min at room temperature. PBMC were collected from the middle layer and washed with running buffer (Miltenyi Biotech, Auburn, CA, USA) at 400 x g for 10 min at 4 °C. The isolated cell pellets were dissolved in RLT plus lysis buffer (Qiagen, Valencia, CA, USA) with 1% 2-mercaptoethanol for 30 min on ice before freezing for storage.
After isolating PBMCs from blood by density gradient centrifugation, PBMCs were labeled with different antibodies to measure the distribution of different subsets. Isolated PBMCs (100 μl) were labeled individually with CD2-FITC (Clone RPA-2.10, BD Pharmingen), CD14-FITC (Clone M5E2, BD Pharmingen), CD20-PE (Clone 2H7 BD Pharmingen) and CD56-PE (Clone NCAM16.2, BD Biosciences) for differentiating T cells, monocytes, B cells and NK cells, respectively. After labeling the PBMCs, flow cytometry was performed with BD FACSCalibur (BD Biosciences, San Jose, CA) and by enumerating 10,000 events (cells) per sample. Flow cytometer data was analyzed by using 9.3.1 version of flow Jo software (FlowJo, LLC. Ashland, Oregon). The Tukey–Krammer honest significant difference test (α = 0.05) was used to compare the mean values of the PBMC subtypes among cohorts.
Microarray experiments
The RNA was prepared from PBMC lysates by SeqWright DNA Technology Services (Houston, TX, USA). Using standard procedures, total RNA was isolated using the Qiagen RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA), RNA concentrations were determined using a Nanodrop ND-100 spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA), and RNA quality was determined by Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Gene expression profiling was performed using Affymetrix Human Genome U133 Plus 2.0 microarray (Affymetrix, Inc., Santa Clara, CA, USA). The expression of ~47,000 transcripts were analyzed by using 100 ng of RNA sample for double-stranded cDNA synthesis, in vitro transcription of cRNA with biotin labelling and hybridization of cRNA on the microarray. The assay was performed using the Affymetrix standard protocol GeneChip® 3’ IVT Express Kit User Manual (P/N 702646 Rev. 1) and the GeneChip® Expression Analysis Technical Manual With Specific Protocols for Using the GeneChip Hybridization, Wash, and Stain Kit (P/N 702232 Rev. 3).
Microarray analysis
Microarray data analyses were performed using either Partek’s Genomics Suite Software (Partek, Inc., St. Louis, MO, USA) or the Bioconductor package in R [26]. Prior to analysis, the Partek Batch Remover method was used to remove batch effects caused by variability in reagents, arrays and equipment. All data were normalized using the Robust Multi-array Analysis (RMA) method. Statistical analysis was performed using pair-wise Analysis of Variance (ANOVA) and correcting for type-I error using the False Discovery Rate (FDR) adjustment method [27]. A minimum fold change of greater than 1.25 for up-regulation and less than −1.25 for down-regulation was established as the criteria for differential expression. An FDR adjusted p-value of <0.05 was considered statistically significant. Hierarchical clustering and Principal Component Analyses (PCA) were performed using the subset of DEGs identified by pairwise analyses to examine similarities between subjects based on their gene expression profiles. Hierarchical clustering was performed using Ward’s minimum variance method, which aims to find compact spherical clusters by minimizing the within-cluster variance using an optimal value of an objective function (error sum of squares).
Random Forest classification models were built using ‘randomForest’ library in R. For each pair of groups (NTC-SMK, NTC-MSC, and MSC-SMK), the data were randomly divided into equal number of training and test subjects. The Random Forest was built using the training group and the accuracy, sensitivity, and specificity of the model was determined using the test group. We repeated this process 50 times and calculated the average classification accuracy, sensitivity and specificity for the 50 runs. The average Gini importance measure for the 50 runs is reported to indicate the influence of each gene in correctly classifying samples in their appropriate groups. Higher Gini values indicate the relative strength of a particular gene in classifying the samples.
Thomson Reuters (New York, NY, USA) performed pathway analysis on the set genes whose expression levels were significantly affected between SMK group and either MSC or NTC group. This analysis utilized data from the GeneGo Global Network, which contains information on ~24,000 proteins, 2859 compounds, and more than one million interactions. An enrichment analysis was performed, which evaluated the overlap between the differentially-expressed genes and gene groupings from canonical pathway maps (biological mechanism), process networks (metabolic and signaling processes), toxic pathologies, and disease biomarkers.
Quantitative polymerase chain reaction
To confirm the results obtained by Affymetrix microarray, a TaqMan-based quantitative polymerase chain reaction (qPCR) assay was performed on all 120 subjects in the study. Target genes (n = 44) were selected based on the microarray results as well a selected number of genes (AHRR, CCL4L1, CCR2, KLRD1, MAF, S1PR5, SSPN, & TFEC) which are known to be associated with smoking in the literature. A complete list of genes and RT-PCR probes are provided in Additional file 2: Table S1.
The qPCR analysis was performed by SeqWright DNA Technology Services (Houston, TX, USA). Approximately 120 ng (n = 118) or 40 ng (n = 2) total RNA was digested with DNase I before cDNA synthesis in 10 μL reaction volume using SuperScript VILO cDNA Synthesis kit (Life Technologies, Grand Island, NY, USA). Ten microliters of cDNA reaction mixture from each sample was mixed with 190 μL of nuclease-free water and 200 μL of 2 x Gene Expression Master Mix (Life Technologies, Grand Island, NY, USA), and 100 μL of this mix was loaded into a 384-well The Low Density Array (TLDA) plate. Each sample was loaded into the plate four times. The Applied Biosystems 7900HT Fast System with Software SDS 2.4 (Life Technologies, Grand Island, NY, USA) was used for the qPCR, using the following cycling conditions: stage 1, 50 °C for 2 min; stage 2, 94.5 °C for 10 min; stage 3, 97 °C for 30 s, 59.7 °C for 1 min (40 cycles).
The results of the qPCR analysis were reported as threshold cycle (Ct) values, defined as the fractional cycle number at which the labeled probe emits fluorescence above a fixed threshold. To give a relative ratio of the abundance of the target gene in each sample, the Ct of the target genes were normalized to the Ct of a reference gene (glyceraldehyde 3-phosphate dehydrogenase) using the SDS 2.4, RQ Manager 1.2.1 and DataAssist v3.0.1 software packages (Life Technologies, Grand Island, NY, USA). Statistical significance was determined by paire-wise ANOVA and the p-values were adjusted using Benjamini-Hochberg false discovery rate to correct type-I error (false positive).
Results
Study population
The characteristics of the patient population have been previously reported [23, 24]. A total of 120 generally healthy subjects completed the study, with 40 subjects in each group (SMK, MSC, and NTC). The majority of patients were Caucasian, with a mean age ranging from 45.0 to 47.2 years. The mean years of product use were 25.1 and 20.6 in the SMK and MSC groups, respectively. During the month prior to the study, the mean number of cigarettes per day consumed by the SMK group was 21.5, while the MSC group consumed a mean 6.3 cans per week of moist snuff.
PBMC populations in tobacco consumers
Yield of PBMCs and % positive CD2 and CD56 cells from SMK, MSC and NTC. Yield of total PBMCs from SMK, MSC and NTC cohorts (40 subjects/cohort) are shown on the top panel. % CD2 positive cells from SMK, MSC and NTC cohorts are shown in the middle panel. % CD56 positive cells from SMK, MSC and NTC cohorts are shown in the bottom panel. The Tukey–Krammer honest significant difference test (α = 0.05) was used to compare the mean values among cohorts
Gene expression profiling
Differentially expressed genes between SMK and either MSC or NTC samples. The number of genes which were significantly (q-value < 0.05) up-regulated or down-regulated in pairwise comparisons are shown for each pairwise comparison. The Venn diagrams show the number of overlapping up-regulated or down-regulated genes for SMK-MSC and SMK-NTC pairwise comparisons
In general, the magnitudes of the gene expression changes in both comparisons were very small; only five genes were differentially expressed by more than 2-fold. For instance, the expression of IGHA1, GPR15 and LRRN3 was changed by +2.14, +2.13 and +2.07 fold between SMK and MSC, respectively. In addition, the expression of CCL4 and LRRN3 was changed by −2.46 and +2.34 fold between SMK and NTC, respectively. These results are expected since all of the individuals in this study were generally healthy.
qRT-PCR validation of 20 DEGs that were similarly affected in SMK-MSC and SMK-NTC pairwise comparisons
SMK vs. MSC | SMK vs. NTC | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Microarray | qRT-PCR | Microarray | qRT-PCR | ||||||
Gene Symbol | Gene Name | FC | P-value (adj.)‡ | FC | P-value (adj.)‡ | FC | P-value (adj.)‡ | FC | P-value (adj.)‡ |
Upregulated | |||||||||
GPR15 | G protein-coupled receptor 15 | 2.13 | 0 | 4.75 | 0 | 2.00 | 0 | 4.27 | 0 |
LRRN3 | Leucine rich repeat neuronal 3 | 2.07 | 0 | 2.18 a | 0.0105 | 2.34 | 0 | 2.16 a | 0.0069 |
SASH1 | SAM and SH3 domain containing 1 | 1.93 | 0 | 1.74 | 0 | 1.97 | 0 | 1.84 | 0 |
ADAMDEC1 | ADAM-like decysin 1 | 1.50 | 0.002 | 1.11a | 0.837 | 1.45 | 0.007 | 1.07a | 0.8469 |
PID1 | Phosphotyrosine interaction domain containing 1 | 1.37 | 0.013 | 1.27 a | 0.0037 | 1.31 | 0.004 | 1.84 a | 0 |
CLEC10A | C-type lectin domain family 10, member A | 1.35 | 0.013 | 1.29 a | 0.0201 | 1.31 | 0.018 | 1.26 a | 0.0041 |
TMEM45B | Transmembrane protein 45B | 1.31 | 0.047 | 1.1 | 0.7332 | 1.53 | 0.004 | 1.41 | 0.0526 |
FUCA1 | Fucosidase, α-L-1, tissue | 1.29 | 0.022 | 1.14 | 0.265 | 1.29 | 0.01 | 1.2 | 0.0805 |
Downregulated | |||||||||
PTGDS | Prostaglandin D2 synthase 21 kDa (brain) | −1.54 | 0.007 | −2.18 | 0.0006 | −1.86 | 0 | −2.23 | 0 |
PRSS23 | Serine protease 23 | −1.54 | 0.046 | −1.33 | 0.1248 | −1.98 | 0 | −1.78 | 0.0152 |
KLRB1 | Killer cell lectinlike receptor subfamily B, member 1 | −1.50 | 0 | −1.79 | 0.1368 | −1.47 | 0 | −1.69 | 0.0041 |
PTGDR | Prostaglandin D2 receptor (DP) | −1.38 | 0.04 | −1.41 | 0.265 | −1.55 | 0 | −1.56 | 0.0391 |
FYN | FYN oncogene related to SRC, FGR, YES | −1.38 | 0.045 | −1.29a | 0.5577 | −1.34 | 0.022 | −1.18 a | 0.029 |
NKG7 | Natural killer cell group 7 sequence | −1.36 | 0.046 | −1.51 | 0.0056 | −1.57 | 0 | −1.78 | 0.0001 |
GZMA | Granzyme A (granzyme 1, cytotoxic T lymphocyte associated serine esterase 3) | −1.33 | 0.022 | −1.30 | 0.5038 | −1.46 | 0 | −1.50 | 0.1317 |
TRD | T cell receptor δ locus | −1.33 | 0.047 | - | - | −1.57 | 0 | - | - |
SYTL3 | Synaptotagmin-like 3 | −1.32 | 0.047 | −1.19 | 0.1392 | −1.28 | 0.044 | −1.13 | 0.1654 |
SEPT2 | Septin 2 | −1.30 | 0.034 | −1.08 | 0.837 | −1.26 | 0.033 | −1.02 | 0.9315 |
CACNA2D2 | Calcium channel, voltage-dependent, α2/δ subunit | −1.28 | 0.033 | −1.22 | 0.6041 | −1.48 | 0 | −2.12 | 0.0423 |
GZMM | Granzyme M (lymphocyte metase 1) | −1.26 | 0.025 | −1.10 | 0.5993 | −1.36 | 0 | −1.24 | 0.0805 |
Functional analysis of expression data
Top pathway maps, process networks and diseases for DEGs in SMK-NTC
Top scoring key ontology terms | p-value |
|---|---|
Key Pathway Maps | |
Role of CD8+ Tc1 cells in COPD | 6.56E-04 |
Development_GDNF signaling | 3.91E-03 |
Generation of cytotoxic CD8+ T cells in COPD | 4.24E-03 |
Development_Role of CDK5 in neuronal development | 7.75E-03 |
Immune resonse_HMGB1/TLR signaling pathway | 8.67E-03 |
Key Process Networks | |
Inflammation_NK cell cytotoxicity | 1.53E-05 |
Chemotaxis | 3.53E-04 |
Development_Blood vessel morphogenesis | 4.85E-03 |
Inflammation_Protein C signaling | 6.66E-03 |
Reproduction_Feeding and Neurohormone signaling | 1.54E-02 |
Key Disease | |
Lung diseases, Obstructive | 2.10E-09 |
Hypersensitivity | 6.14E-09 |
Skin Disease, Vascular | 1.13E-08 |
Pulmonary Diseases, Chronic Obstructive | 3.68E-08 |
Asthma, Asprin-Inudced | 3.70E-08 |
Class prediction
Clustering of 120 subjects based on blood expression profiles of 25 genes which were significantly different by ±1.5 fold between SMK and either MSC or NTC subjects. a Hierarchical clustering and heatmap representation of expression values for genes (rows) across 120 subjects (columns), where low expression is denoted by green and high expression by red. The expression of each gene was normalized across all samples. Subjects were categorized into SMK (blue), MSC (red), and NTC (green). b Principal Component Analysis. Subjects were projected according to the first three principal components, which accounted for 35.7% (PC1), 10.0% (PC2) and 6.9% (PC3) of the gene expression variance. Subjects were categorized into SMK (blue squares), MSC (red spheres), and NTC (green triangles). The centroid of each group is depicted by a larger symbol with lines radiating to all of the subjects in that group
Next, we applied Principal Component Analysis (PCA), which is a robust mathematical method for reducing the dimensionality of the data, to visualize the relationships between subjects based on the variation of the 25 differentially expressed genes across all subjects. When subjects were projected using the first three principal components, which accounted for 52.6% of the total variation, we found that the centroids of the MSC and NTC samples were closer together than to SMK samples respectively (Fig. 3b). These results were consistent with the hierarchical clustering results and revealed a number of SMK subjects whose gene expression profiles were similar to NTC and MSC subjects.
SMK-MSC Random Forest Classification. a Average AUC for different number of genes are shown in this figure. The highest AUC of 0.98 is obtained using 15 genes. b Average Gini importance of genes across 50 runs of the model indicates the influence of the genes in correct classification (distinction) of SMK and MSC samples. c ROC curve associated with the model achieving highest AUC
SMK-NTC Random Forest Classification. a Average AUC for different number of genes are shown in this figure. The highest AUC of 0.98 is obtained using 20 genes. b Average Gini importance of genes across 50 runs of the model indicates the influence of the genes in correct classification (distinction) of SMK and NTC samples. c ROC curve associated with the model achieving the highest AUC
As a by-product of training the RF classifier, each gene (variable) can be scored with respect to its influence on splitting a sample into different classes, referred to as the “Gini Importance” value. Using this approach, the influence of each gene on the class prediction can be determined, thereby allowing us to identify the most impactful biomarker genes that distinguish between SMK, MSC, and NTC subjects. GPR15 was the best gene predictor of SMK for both MSC and NTC comparison (Gini values of 9.21 and 7.25, respectively). In addition LRRN3 was the second highest predictor, but with substantially lower Gini values in both comparisons (Gini values 3.86 and 2.74). Significantly, all 15 of the top predictor genes in SMK-MSC were also top ranked for predicting SMK from NTC. These results indicate that there is a distinct set of biomarker genes that distinguish SMK from NTC and MSC groups.
Discussion
In this study, we demonstrated that cigarette smoking results in significant changes in the expression of a small number of genes in PBMCs compared to either moist snuff consumers or people who do not consume tobacco. Notably, this is the first study in which gene expression profiling is conducted in moist snuff consumers. As discussed in the Background section, epidemiological data indicate that US and European smokeless products (snus, in particular) have been associated with reduced risk compared to cigarettes. Consistent with our published work [20, 22–24], which showed that MSC are exposed to reduced levels of combustion-related biomarkers of exposure, MSC exhibited similar gene expression profiles as observed in NTC, but different profiles from SMK. Although the gene expression data are derived from a cross-sectional study, they could support the epidemiological findings in consumers of different classes of tobacco products.
Through Random Forest classification approach we were able to identify a group of genes whose expression levels in PBMCs could accurately (AUC of 0.98) predict SMK from either MSC or NTC groups (Figs. 4 and 5). The top predictor genes for SMK included GPR15, LRRN3, PRSS23, SASH1 and COCH among others. Separately, a 11 gene signature derived from whole blood, consisting of LRRN3, SASH1, PALLD, RGL1, TNFRSF17, CDKN1C, IGJ, RRM2, ID3, SERPING1, and FUCA1 genes was reported to distinguish current smokers from nonsmokers and former smokers [28]. Interestingly, several genes (LRRN3, SASH1 and IGJ) were common to the discriminating set of genes for SMK-NTC comparison (Fig. 5) and the published signature [28].
GPR15 gene encodes a G protein coupled receptor which acts as a chemokine receptor. Consistent with our findings, several studies have shown that GPR15 expression levels and methylation status is associated with smoking and chronic inflammatory pathologies [29–32]. Similarly, the expression and methylation levels of LRRN3 (Leucine rich repeat protein 3) have been associated with smoking in various studies [5, 32, 33]. SASH 1 (SAM and SH3 domain containing 1) expression levels have also been associated with smoking and smoking-related atherosclerosis [28, 34]. SASH1 is believed to be a tumor suppressor in breast and colon cancer and has been shown to inhibit cell migration and enhance cell adhesion of epithelial cells [35]. An increased expression of SASH1 in our study may reflect a host immune response to counteract smoking. The PRSS23 (protease, serine 23) belongs to trypsin family of serine proteases. The PRSS23 gene methylation status is correlated with smoking, but its expression does not appear to be different in the whole blood cells from smokers [36]. Our data, however, show that there is a downregulation of PRSS23 in PBMCs of SMK when compared to NTC and MSC (micro array data), and in SMK vs NTC (RT-PCR) (Table 1). PRSS23 is suggested to regulate cellular proliferation and cancer [37]. In contrast, there is no evidence in the literature which associates COCH (cochlin) with smoking. Thus our studies have identified several established gene expression markers for smoking and have revealed additional marker genes which may provide insights into future smoking research.
Cigarette smoke exposure appears to affect pathways involved in immune response, chemotaxis, as well as inflammatory disorders and lung diseases. Genes involved in stress response or metabolism known to be associated with smoke exposure were not identified in the functional analysis in either the SMK versus MSC comparison or the SMK versus NTC comparison. This suggests that the effect of different categories of tobacco products on molecular pathways could be tissue specific and product category specific. For instance, in airway epithelium and the nasal and oral mucosa, cigarette smoke has been shown to affect pathways involved in inflammation, cell adhesion, tumor suppression, oxidative stress, detoxification, and carcinogen metabolism [3, 4, 38–42]. Studies of the effect of cigarette smoke on monocytes support the results of the present study, with genes related to inflammation, immune response, cell survival, and protein transport affected by cigarette smoke or its constituents [43–45].
qRT-PCR validation of expression changes that were unique to either SMK-NTC or SMK-MSC comparison
SMK vs. MSC | SMK vs. NTC | MSC vs. NTC | |||||
|---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | FC | P-value (adj.)‡ | FC | P-value (adj.)‡ | FC | P-value (adj.)‡ |
Unique to SMK vs. NTC | |||||||
ADRB2 | adrenoceptor beta 2 | −1.44 | 0.0037 | −1.61 | 0.0003 | −1.11 | 0.5527 |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | −1.13 | 0.6507 | −1.95 | 0.0358 | −1.73 | 0.2651 |
CCL4 | chemokine (C-C motif) ligand 4 | 2.67 | 0.4409 | −7.43 | 0.0815 | −19.84 | 0.254 |
CCR2a | C-C motif chemokine receptor 2 | −1.13 | 0.648 | 1.15 | 0.4312 | 1.09 | 0.741 |
CD160 | CD160 molecule | −1.16 | 0.4317 | −1.64 | 0.0008 | −1.42 | 0.0572 |
CST7 | cystatin F | −1.52 | 0.0045 | −1.71 | 0 | −1.13 | 0.5229 |
DTHD1 | death domain containing 1 | −1.55 | 0.0221 | −1.57 | 0.0312 | −1.01 | 0.9647 |
ENPP5 | ectonucleotide pyrophosphatase/phosphodiesterase 5 | −1.03 | 0.945 | −1.41 | 0.3163 | −1.37 | 0.4482 |
GPR56 | G protein-coupled receptor 56 | −1.73 | 0.0079 | −1.78 | 0.0002 | −1.02 | 0.8987 |
GZMH | granzyme H | −1.61 | 0.0234 | −1.96 | 0.0039 | −1.22 | 0.5751 |
HHEX | hematopoietically expressed homeobox | 1.00 | 0.9664 | 1.09 | 0.5279 | 1.08 | 0.7028 |
KLRD1a | killer cell lectin like receptor D1 | −1.36 | 0.0201 | −1.71 | 0.0001 | −1.26 | 0.2944 |
KLRF1 | killer cell lectin like receptor F1 | 1.07 | 0.9335 | −1.34 | 0.5279 | −1.43 | 0.5229 |
LPAR6 | lysophosphatidic acid receptor 6 | −1.49 | 0.0215 | −1.07 | 0.7594 | 1.39 | 0.2651 |
MAFa | v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog | 1.70 | 0.0215 | −1.30 | 0.0566 | −1.73 | 0.1712 |
PRF1 | perforin 1 | −1.40 | 0.0091 | −1.67 | 0.0002 | −1.19 | 0.4482 |
S1PR5a | sphingosine-1-phosphate receptor 5 | 1.65 | 0.0676 | −1.82 | 0.0391 | −3.00 | 0.0284 |
SH2D1B | SH2 domain containing 1B | −1.16 | 0.648 | −1.70 | 0.0312 | −1.46 | 0.254 |
SOCS6 | suppressor of cytokine signaling 6 | 1.05 | 0.8367 | 1.12 | 0.5279 | 1.06 | 0.741 |
TBX21 | T-box 21 | −1.27 | 0.0796 | −1.52 | 0.0009 | −1.20 | 0.2997 |
TFECa | transcription factor EC | 1.34 | 0.5993 | −1.09 | 0.8409 | −1.46 | 0.5229 |
TGFBR3 | transforming growth factor beta receptor III [ | −1.38 | 0.0079 | −1.60 | 0.0001 | −1.16 | 0.4726 |
Unique to SMK vs. MSC | |||||||
ADM | adrenomedullin | 1.66 | 0.0215 | −1.19 | 0.4309 | −1.98 | 0.0393 |
SSPNa | sarcospan | −1.71 | 0.648 | −1.30 | 0.1379 | −1.28 | 0.5164 |
AHRRa | aryl-hydrocarbon receptor repressor | 3.54 | 0.0037 | 3.11 | 0.0041 | −1.14 | 0.8324 |
Our qRT-PCR experiments confirmed some well-known complexities associated with global profiling methods in general, and microarray approaches in this particular case. First, not all probes on the microarray may be appropriate for detecting the transcript levels for a given gene. For instance, microarray analysis did not detect a change in aryl hydrocarbon receptor repressor (AHRR) gene between SMK and NTC. AHRR, a well-established repressor and regulator of aryl hydrocarbon receptor (AHR) [50], is widely reported to be hypermethylated in smokers [51]. In contrast to microarray results, our qRT-PCR analysis showed that AHRR transcript was elevated in smokers and was expressed at comparable levels in both SMK-NTC and SMK-MSC comparisons (Table 3). Our finding that smokers exhibit higher levels of AHRR in PBMCs differs from that of other investigators [36] who did not find differences in AHRR transcript levels between whole blood of smokers and non-smokers, perhaps reflecting on the cell types that comprised the starting materials for gene expression analysis. Second, microarray analysis did not reveal any statistically significant differences between MSC and NTC groups after FDR correction. However, qRT-PCR analysis revealed at least two genes (ADM and S1PR) which were significantly changed between SMK and MSC. It is generally recognized that FDR adjustment methods, while necessary to correct for multiple hypothesis testing error, can be too stringent and result in false negatives [27, 52–54].
Several previous studies (reviewed in [51]) have shown that AHRR hypomethylation occurs in smokers, potentially activating aryl hydrocarbon receptor signaling pathway. Consistently, we have found that in buccal cells collected from the same cohort of SMK, several AHRR gene loci were prominently hypomethylated. AHRR methylation is not altered in MSC relative to NTC (manuscript in preparation).
Conclusions
In summary, in this first genome-wide expression analysis of moist snuff consumers, we found MSC expression profiles are very similar to NTC, while SMK exhibit a distinct gene expression profile. Specifically, previously described markers associated with smokers, such as AHRR, GPR15, LRNN3, COCH and PRSS23 may serve as biomarkers to distinguish different tobacco product consumers.
Under the Family Smoking Prevention and Tobacco Control Act, FDA has banned the terms “Full Flavor Lights” or “Full Flavor” as a cigarette descriptor as of June 22, 2010. However, at the time of this study, these terms were used (based on tar content/cigarette), thus the “tar” term is included in this manuscript as it accurately reflects the products evaluated prior to such date.
Abbreviations
- DEGs:
-
Differentially expressed genes
- MSC:
-
Moist snuff consumers
- NTC:
-
Non-tobacco consumers
- PBMC:
-
Peripheral blood mononuclear cells
- SMK:
-
Smokers
- STP:
-
Smokeless tobacco products
Declarations
Acknowledgements
The authors sincerely thank Dr. Bobbette A. Jones for managing the clinical conduct of the biomarker discovery study.
Funding/support
The study was funded by R.J. Reynolds Tobacco Company (“RJRT”). Employees of RJRT and its affiliated company, RAI Services Company, were variously involved in the design and management of the study conduct, data collection, analysis, and/or manuscript preparation.
Availability of data and material
The gene expression profiles were deposited in GEO repository with an accession number GSE87072 and the data are publicly available.
Authors’ contributions
SA isolated PBMCs from the blood samples of study subjects, enumerated select subtypes. PC performed statistical analyses. KM contributed to the preparation of the manuscript. BM performed the microarray analysis. GLP designed and managed the study, and prepared the manuscript. All authors read and approved the final manuscript.
Competing interests
G. L. Prasad, Peter Chen and Kristin Marano are full time employees of RAI Services Company, which is a subsidiary of Reynolds American Inc. Behrouz Madahian is a full time employee of Quire Inc.
Consent for publication
N/A.
Ethics approval and consent to participate
The study was approved by a central institutional review board (Independent Investigational Review Board, Inc., Plantation, FL, USA), and a written Informed Consent was obtained from the study participants prior to enrolling in to the study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
References
- U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress, A report of the Surgeon General. Atlanta: U.S. DHHS, Centers for Disease Control and Prevention, Office on Smoking and Health; 2014.Google Scholar
- U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General, A report of the Surgeon General. Atlanta: Centers for Disease Control and Prevention. Office on Smoking and Health; 2010.Google Scholar
- Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, Palma J, Brody JS. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A. 2004;101(27):10143–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, Liu G, Dumas Y-M, Zhang X, Brody JS, et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics. 2008;9:259.View ArticlePubMedPubMed CentralGoogle Scholar
- Beineke P, Fitch K, Tao H, Elashoff MR, Rosenberg S, Kraus WE, Wingrove JA. A whole blood gene expression-based signature for smoking status. BMC Med Genomics. 2012;5(1):1–9.View ArticleGoogle Scholar
- Weng DY, Chen J, Taslim C, Hsu PC, Marian C, David SP, Loffredo CA, Shields PG. Persistent alterations of gene expression profiling of human peripheral blood mononuclear cells from smokers. Mol Carcinog. 2016;55(10):1424–37.View ArticlePubMedGoogle Scholar
- Na HK, Kim M, Chang SS, Kim SY, Park JY, Chung MW, Yang M. Tobacco smoking-response genes in blood and buccal cells. Toxicol Lett. 2015. 232(2):429–37.View ArticlePubMedGoogle Scholar
- Gower AC, Steiling K, Brothers 2nd JF, Lenburg ME, Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc Am Thorac Soc. 2011;8(2):173–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Piano MR, Benowitz NL, Fitzgerald GA, Corbridge S, Heath J, Hahn E, Pechacek TF, Howard G. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation. 2010;122(15):1520–44.View ArticlePubMedGoogle Scholar
- Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. The chemical composition of smokeless tobacco: a survey of products sold in the United States in 2006 and 2007. Regul Toxicol Pharmacol. 2012;64(3):367–87.View ArticlePubMedGoogle Scholar
- Yatsuya H, Folsom AR. Risk of incident cardiovascular disease among users of smokeless tobacco in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2010;172(5):600–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control. 2005;16(4):347–58.View ArticlePubMedGoogle Scholar
- Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA. 2000;284(6):706–12.View ArticlePubMedGoogle Scholar
- U.S. Department of Health and Human Services. Reducing the Health Cunsequences of Smoking: 25 Years of Progress. A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS Publication No. (CDC) 89-8411. 1989.Google Scholar
- Hatsukami DK, Joseph AM, Lesage M, Jensen J, Murphy SE, Pentel PR, Kotlyar M, Borgida E, Le C, Hecht SS. Developing the science base for reducing tobacco harm. Nicotine Tob Res. 2007;9 Suppl 4:S537–553.View ArticlePubMedPubMed CentralGoogle Scholar
- Zeller M, Hatsukami D, Strategic Dialogue on Tobacco Harm Reduction Group. The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control. 2009;18(4):324–32.View ArticlePubMedPubMed CentralGoogle Scholar
- Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerstrom K, Letlape K, Milton A, Polosa R, et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res. 2014;20(5):218–25.View ArticlePubMedGoogle Scholar
- Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control. 2003;12(4):349–59.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee PN. Epidemiological evidence relating snus to health—an updated review based on recent publications. Harm reduct J. 2013;10:36.View ArticlePubMedPubMed CentralGoogle Scholar
- Campbell LR, Brown BG, Jones BA, Marano KM, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers, part 1: biomarkers of exposure. Inhal Toxicol. 2015;27(3):149–56.View ArticlePubMedPubMed CentralGoogle Scholar
- Marano KM, Kathman SJ, Jones BA, Nordskog BK, Brown BG, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers. Part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey. Inhal Toxicol. 2015;27(3):167–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Nordskog BK, Brown BG, Marano KM, Campell LR, Jones BA, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. Inhal Toxicol. 2015;27(3):157–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Prasad GL, Jones BA, Chen P, Gregg EO. A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers. Clin Chem Lab Med. 2016;54(4):633–42.View ArticlePubMedGoogle Scholar
- Prasad GL, Schmidt E, Chen P, Kennedy AD. Global metabolomic profiles reveal differences in oxidative stress and inflammation pathways in smokers and moist snuff consumers. J Metabolomics. 2015;1. http://dx.doi.org/10.7243/2059-0008-1-2.
- Arimilli S, Damratoski BE, Chen P, Jones BA, Prasad GL. Rapid isolation of leukocyte subsets from fresh and cryopreserved peripheral blood mononuclear cells in clinical research. Cryo Letters. 2012;33(5):376–84.PubMedGoogle Scholar
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.View ArticlePubMedPubMed CentralGoogle Scholar
- Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100(16):9440–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Martin F, Talikka M, Hoeng J, Peitsch MC. Identification of gene expression signature for cigarette smoke exposure response—from man to mouse. Hum Exp Toxicol. 2015;34(12):1200–11.View ArticlePubMedGoogle Scholar
- Dogan MV, Shields B, Cutrona C, Gao L, Gibbons FX, Simons R, Monick M, Brody GH, Tan K, Beach SR, et al. The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women. BMC Genomics. 2014;15:151.View ArticlePubMedPubMed CentralGoogle Scholar
- Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, Agusti A, Anderson W, Lomas DA, Demeo DL. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet. 2012;21(13):3073–82.View ArticlePubMedPubMed CentralGoogle Scholar
- Koks G, Uudelepp ML, Limbach M, Peterson P, Reimann E, Koks S. Smoking-induced expression of the GPR15 gene indicates its potential role in chronic inflammatory pathologies. Am J Pathol. 2015;185(11):2898–906.View ArticlePubMedGoogle Scholar
- Obeidat M, Ding X, Fishbane N, Hollander Z, Ng RT, McManus B, Tebbutt SJ, Miller BE, Rennard S, Pare PD, et al. The effect of different case definitions of current smoking on the discovery of smoking-related blood gene expression signatures in chronic obstructive pulmonary disease. Nicotine Tob Res. 2016. 18(9):1903–9.View ArticlePubMedGoogle Scholar
- Guida F, Sandanger TM, Castagne R, Campanella G, Polidoro S, Palli D, Krogh V, Tumino R, Sacerdote C, Panico S, et al. Dynamics of smoking-induced genome-wide methylation changes with time since smoking cessation. Hum Mol Genet. 2015;24(8):2349–59.View ArticlePubMedPubMed CentralGoogle Scholar
- Weidmann H, Touat-Hamici Z, Durand H, Mueller C, Chardonnet S, Pionneau C, Charlotte F, Janssen KP, Verdugo R, Cambien F, et al. SASH1, a new potential link between smoking and atherosclerosis. Atherosclerosis. 2015;242(2):571–9.View ArticlePubMedGoogle Scholar
- Martini M, Gnann A, Scheikl D, Holzmann B, Janssen KP. The candidate tumor suppressor SASH1 interacts with the actin cytoskeleton and stimulates cell-matrix adhesion. Int J Biochem Cell Biol. 2011;43(11):1630–40.View ArticlePubMedGoogle Scholar
- Tsaprouni LG, Yang TP, Bell J, Dick KJ, Kanoni S, Nisbet J, Vinuela A, Grundberg E, Nelson CP, Meduri E, et al. Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics. 2014;9(10):1382–96.View ArticlePubMedPubMed CentralGoogle Scholar
- Chan HS, Chang SJ, Wang TY, Ko HJ, Lin YC, Lin KT, Chang KM, Chuang YJ. Serine protease PRSS23 is upregulated by estrogen receptor alpha and associated with proliferation of breast cancer cells. PLoS One. 2012;7(1):e30397.View ArticlePubMedPubMed CentralGoogle Scholar
- Beane J, Vick J, Schembri F, Anderlind C, Gower A, Campbell J, Luo L, Zhang XH, Xiao J, Alekseyev YO, et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res (Phila Pa). 2011;4(6):803–17.View ArticleGoogle Scholar
- Beane J, Cheng L, Soldi R, Zhang X, Liu G, Anderlind C, Lenburg ME, Spira A, Bild AH. SIRT1 pathway dysregulation in the smoke-exposed airway epithelium and lung tumor tissue. Cancer Res. 2012;72(22):5702–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Boyle JO, Gumus ZH, Kacker A, Choksi VL, Bocker JM, Zhou XK, Yantiss RK, Hughes DB, Du B, Judson BL, et al. Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res (Phila Pa). 2010;3(3):266–78.View ArticleGoogle Scholar
- Hubner R-H, Schwartz JD, De Bishnu P, Ferris B, Omberg L, Mezey JG, Hackett NR, Crystal RG. Coordinate control of expression of Nrf2-modulated genes in the human small airway epithelium is highly responsive to cigarette smoking. Mol Med. 2009;15(7–8):203–19.PubMedPubMed CentralGoogle Scholar
- Zhang X, Sebastiani P, Liu G, Schembri F, Zhang X, Dumas YM, Langer EM, Alekseyev Y, O’Connor GT, Brooks DR, et al. Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol Genomics. 2010;41(1):1–8.View ArticlePubMedGoogle Scholar
- Doyle I, Ratcliffe M, Walding A, Vanden Bon E, Dymond M, Tomlinson W, Tilley D, Shelton P, Dougall I. Differential gene expression analysis in human monocyte-derived macrophages: impact of cigarette smoke on host defence. Mol Immunol. 2010;47(5):1058–65.View ArticlePubMedGoogle Scholar
- van Leeuwen DM, Gottschalk RW, van Herwijnen MH, Moonen EJ, Kleinjans JC, van Delft JH. Differential gene expression in human peripheral blood mononuclear cells induced by cigarette smoke and its constituents. Toxicol Sci. 2005;86(1):200–10.View ArticlePubMedGoogle Scholar
- Wright WR, Parzych K, Crawford D, Mein C, Mitchell JA, Paul-Clark MJ. Inflammatory transcriptome profiling of human monocytes exposed acutely to cigarette smoke. PLoS One. 2012;7(2):e30120.View ArticlePubMedPubMed CentralGoogle Scholar
- Arimilli S, Damratoski BE, Bombick B, Borgerding MF, Prasad GL. Evaluation of cytotoxicity of different tobacco product preparations. Regul Toxicol Pharmacol. 2012;64(3):350–60.View ArticlePubMedGoogle Scholar
- Gao H, Prasad GL, Zacharias W. Differential cell-specific cytotoxic responses of oral cavity cells to tobacco preparations. Toxicol in Vitro. 2013;27(1):282–91.View ArticlePubMedGoogle Scholar
- Arimilli S, Damratoski BE, Prasad GL. Combustible and non-combustible tobacco product preparations differentially regulate human peripheral blood mononuclear cell functions. Toxicol in Vitro. 2013;27(6):1992–2004.View ArticlePubMedGoogle Scholar
- Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol. 2008;83(3):774–84.View ArticlePubMedGoogle Scholar
- Hahn ME, Allan LL, Sherr DH. Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor. Biochem Pharmacol. 2009;77(4):485–97.View ArticlePubMedGoogle Scholar
- Gao X, Jia M, Zhang Y, Breitling LP, Brenner H. DNA methylation changes of whole blood cells in response to active smoking exposure in adults: a systematic review of DNA methylation studies. Clin Epigenetics. 2015;7:113.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu L, Cheng C, George EO, Homayouni R. Literature aided determination of data quality and statistical significance threshold for gene expression studies. BMC Genomics. 2012;13(8):S23.PubMedPubMed CentralGoogle Scholar
- Xu L, Furlotte N, Lin Y, Heinrich K, Berry MW, George EO, Homayouni R. Functional cohesion of gene sets determined by latent semantic indexing of PubMed abstracts. PLoS One. 2011;6(4):e18851.View ArticlePubMedPubMed CentralGoogle Scholar
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.View ArticlePubMedPubMed CentralGoogle Scholar
